Evidence map›Paper›PMID 32845905›Full record

ArticlePloS one2020

Cherenkov emissions for studying tumor changes during radiation therapy: An exploratory study in domesticated dogs with naturally-occurring cancer.

Ashlyn G Rickard, Hiroto Yoshikawa, Gregory M Palmer, Harrison Q Liu, Mark W Dewhirst, Michael W Nolan, Xiaofeng Zhang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ashlyn G RickardDepartment of Radiation Oncology, Program of Medical Physics, Duke University School of Medicine, Durham, NC, United States of America.
Hiroto YoshikawaDepartment of Clinical Sciences, College of Veterinary Medicine, NC State University, Raleigh, NC, United States of America.ORCID 0000-0001-8249-1525
Gregory M PalmerDepartment of Radiation Oncology, Program of Medical Physics, Duke University School of Medicine, Durham, NC, United States of America.
Harrison Q LiuProgram of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Mark W DewhirstDepartment of Radiation Oncology, Program of Medical Physics, Duke University School of Medicine, Durham, NC, United States of America.
Michael W NolanDepartment of Clinical Sciences, College of Veterinary Medicine, NC State University, Raleigh, NC, United States of America.
Xiaofeng ZhangArtificial Intelligence, Marchex Inc., Seattle, WA, United States of America.ORCID 0000-0002-3566-9084
North Carolina State University · USDuke University · USUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeReal-time monitoring of physiological changes of tumor tissue during radiation therapy (RT) could improve therapeutic efficacy and predict therapeutic outcomes. Cherenkov radiation is a normal byproduct of radiation deposited in tissue. Previous studies in rat tumors have confirmed a correlation between Cherenkov emission spectra and optical measurements of blood-oxygen saturation based on the tissue absorption coefficients. The purpose of this study is to determine if it is feasible to image Cherenkov emissions during radiation therapy in larger human-sized tumors of pet dogs with cancer. We also wished to validate the prior work in rats, to determine if Cherenkov emissions have the potential to act an indicator of blood-oxygen saturation or water-content changes in the tumor tissue-both of which have been correlated with patient prognosis.

methodsA DoseOptics camera, built to image the low-intensity emission of Cherenkov radiation, was used to measure Cherenkov intensities in a cohort of cancer-bearing pet dogs during clinical irradiation. Tumor type and location varied, as did the radiation fractionation scheme and beam arrangement, each planned according to institutional standard-of-care. Unmodulated radiation was delivered using multiple 6 MV X-ray beams from a clinical linear accelerator. Each dog was treated with a minimum of 16 Gy total, in ≥3 fractions. Each fraction was split into at least three subfractions per gantry angle. During each subfraction, Cherenkov emissions were imaged.

resultsWe documented significant intra-subfraction differences between the Cherenkov intensities for normal tissue, whole-tumor tissue, tissue at the edge of the tumor and tissue at the center of the tumor (p<0.05). Additionally, intra-subfraction changes suggest that Cherenkov emissions may have captured fluctuating absorption properties within the tumor.

conclusionHere we demonstrate that it is possible to obtain Cherenkov emissions from canine cancers within a fraction of radiotherapy. The entire optical spectrum was obtained which includes the window for imaging changes in water and hemoglobin saturation. This lends credence to the goal of using this method during radiotherapy in human patients and client-owned pets.

Indexed as

X-RaysAnimalsDogsImage Processing, Computer-AssistedNeoplasmsParticle AcceleratorsPilot ProjectsProspective StudiesRadiotherapy DosageTomography, X-Ray Computed

Identifiers

PMID32845905
PMCPMC7449466
OpenAlexW3080902157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.